AbbVie and Turnstone Biologics have entered a research, option and license agreement under which AbbVie obtained an exclusive option to license as many as three of Turnstone’s next-generation oncolytic viral immunotherapies. Financial terms were not disclosed.   Oncolytic viruses take advantage of defective pathways in tumors to selectively replicate in and destroy cancer cells, while cancer vaccines create killer (CD8+) T cell immune responses against tumor antigens.     Turnstone eng...